American Pathway Fixed Annuity II 7-Year review

Depends. If you're already an Edward Jones client and want a simple, guaranteed-rate holding for a 7-year time horizon, this is a clean, well-structured MYGA with better-than-typical liquidity terms. If you're rate-shopping across the open MYGA market, the guaranteed rate here is unlikely to be the most competitive 7-year option available, and being locked into a single distribution channel means you can't negotiate or compare it directly against competing carriers before buying.

The rational reason to buy this is certainty within a familiar relationship. An Edward Jones client who wants a guaranteed rate locked for seven years, without index formulas or rider decisions to evaluate, gets exactly that here. The free-withdrawal and RMD terms are genuinely useful if some liquidity might be needed along the way, and the terminal illness and extended-care waivers add a layer of protection that plain MYGAs often skip. For someone who values simplicity and already trusts their advisor relationship, that combination is a reasonable trade.

This fits an Edward Jones client, typically approaching or in retirement, who has at least $25,000 in funds — qualified or non-qualified — they can commit for seven years and wants a guaranteed rate rather than index-linked growth potential. It's a poor fit for someone shopping the broader MYGA market for the highest available rate, since this product isn't sold outside the Edward Jones channel and its current rate is not top-of-market.

You're buying a fixed-rate insurance contract, not an investment. Corebridge (through American General Life Insurance Company) guarantees a stated interest rate — 4.55% below $100,000 or 4.85% at $100,000 and above as of this writing (rising to 4.70%/5.00% on contracts issued on or after 5/11/2026) — for the full seven-year surrender period. After that guarantee period ends, the rate doesn't lock again automatically; it resets annually at whatever new rate Corebridge declares, which could be higher or lower. Underneath the current rate sits a minimum guaranteed surrender value (MGSV) of 87.5% of premium, growing at 0.15% to 3% depending on state — a floor that protects you in a falling-rate environment, though it's meaningfully lower than what you'd get by simply holding the contract to term at the stated rate.

The core feature is the fixed rate itself. Unlike an indexed annuity, there's no formula, cap, or participation rate to interpret — Corebridge declares a rate, and that rate applies to the full account value for the length of the guarantee period (here, all seven years). The published rates are tiered by premium size: 4.55%/4.85% currently, moving to 4.70%/5.00% on 5/11/2026, so the timing of a purchase around a rate change matters more here than it would with an indexed product. Once the seven-year guarantee expires, the contract doesn't mature outright — it rolls into an annually renewing rate that Corebridge sets going forward, so a long-term holder takes on renewal-rate risk beyond year seven unless they surrender or annuitize at that point.

The second-most-important feature is the free-withdrawal and waiver package, which is stronger than a lot of MYGAs in this surrender band. Owners can take out 10% of the prior anniversary value each year after the first contract year with no surrender charge or MVA, and RMDs tied to this contract can be taken at any time without penalty. On top of that, the surrender charge and MVA are waived entirely for a qualifying terminal illness diagnosis or for extended care lasting 90+ consecutive days beginning after year one (that waiver sunsets at age 86). For a product built around a long rate lock, that combination meaningfully softens the downside if life circumstances change.

Seven years is a real commitment, and the surrender schedule below reflects that — starting at 7% in year one and stepping down to 1% by year seven, with a market value adjustment (MVA — a mechanism that lets the surrender penalty move with interest rates rather than staying fixed) layered on top of any surrender-charge withdrawal. That means a withdrawal in a rising-rate environment could cost more than the surrender charge alone suggests. Still, the free-withdrawal allowance (10% of the prior anniversary value annually, after leaving a $2,000 minimum balance) and the unrestricted RMD carve-out give this contract more breathing room than a bare-bones MYGA. The terminal illness and extended-care waivers add a further safety valve, but none of that changes the basic math: this product is built to be held for the full seven years, and treating it as a source of near-term cash beyond the free allowance will cost money.

There's no explicit rider fee here because there's no income or living-benefit rider to attach one to, and the spec discloses no base contract fee either. The real cost of this product isn't a line-item charge; it's the rate itself relative to what else is available. At 4.55%-4.85% (soon 4.70%-5.00%), the guaranteed yield is respectable but not standout for a 7-year lock in the current rate environment, where the strongest MYGAs of comparable duration are pricing meaningfully higher. The other tradeoff worth naming is opportunity cost from the Edward Jones exclusivity: because this product isn't sold in the open market, there's no way to negotiate or directly compare it against a competing carrier's 7-year MYGA before committing.

Legal Entity: American General Life Insurance Company

A.M. Best Rating: A